TGF-β Inhibition Through Combinatory Strategies Suppresses Proliferation and Invasiveness in Malignant Pleural Mesothelioma
International Journal of Molecular Sciences · 25.02.2026 · 27 (5) · 2157
DOI: 10.3390/ijms27052157 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.02.2026. Verfasst von Valeria Ramundo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Torino, Via Santena, 5/bis, 10126 Torino, Italy. Hauptthemen laut MEDLINE: Transforming Growth Factor beta, Mesothelioma, Pleural Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italy's Foundation "Fondazione CRT", Italy’s Foundation “Fondazione CRT”.
Abstract (Originalsprache)
Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor associated with asbestos exposure, which represents a current problem. MPM is characterized by a poor prognosis and an unsatisfactory therapeutic approach. Therefore, improving MPM prognosis is the real challenge for research today. Regarding preclinical data, Transforming Growth Factor-β (TGF-β) plays a crucial role in cancer, and its alteration has been associated with tumor progression and invasiveness, in particular through the Epithelial to Mesenchymal Transition (EMT) event. We investigated the role of TGF-β inhibition in proliferation, cell cycle, migration, and invasiveness in human MPM cells. Data obtained clearly highlighted how TGF-β inhibition, through the silencing or treatment of MPM cells with antibody anti-TGF-β (Fresolimumab), significantly reduces cell proliferation (MTT, PCNA) and prevents metastasis, reducing EMT and decreasing the invasiveness and migration of MPM cells. Finally, we also evaluated TGF-β inhibitory effects in 3D MPM cellular models (spheroids), highlighting a significant slowdown in the growth rate of spheroids treated with anti-TGF-β antibody or Fresolimumab, confirming the results previously obtained. Taken as a whole, targeting TGF-β will represent a starting point for future improvements in MPM management. This is particularly important as we foresee a growing increase in MPM in the coming years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, University of Torino, Via Santena, 5/bis, 10126 Torino, Italy.
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza, 52, 10126 Torino, Italy.
- Interdepartmental Center for Studies on Asbestos and Other Toxic Particulates "G. Scansetti", University of Torino, 10126 Torino, Italy.
- Molecular Biotechnology Center "Guido Tarone", University of Torino, Piazza Nizza, 44, 10126 Torino, Italy.
ORCID-Profile: Valeria Ramundo, Joanna Kopecka, Elisabetta Aldieri
Förderung
- Italy's Foundation "Fondazione CRT"
- Italy’s Foundation “Fondazione CRT”
Zitieren
APA
Ramundo, V., Palazzo, M. L., Lignola, S., Raimondo, D., Kopecka, J., & Aldieri, E. (2026). TGF-β Inhibition Through Combinatory Strategies Suppresses Proliferation and Invasiveness in Malignant Pleural Mesothelioma. International Journal of Molecular Sciences, 27(5), 2157. https://doi.org/10.3390/ijms27052157
Vancouver
Ramundo V, Palazzo ML, Lignola S, Raimondo D, Kopecka J, Aldieri E. TGF-β Inhibition Through Combinatory Strategies Suppresses Proliferation and Invasiveness in Malignant Pleural Mesothelioma. International Journal of Molecular Sciences. 2026;27(5):2157. doi:10.3390/ijms27052157
BibTeX
@article{Ramundo2026,
author = {Ramundo, Valeria and Palazzo, Maria Luisa and Lignola, Stefania and Raimondo, Daniela and Kopecka, Joanna and Aldieri, Elisabetta},
title = {TGF-β Inhibition Through Combinatory Strategies Suppresses Proliferation and Invasiveness in Malignant Pleural Mesothelioma},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {5},
pages = {2157},
doi = {10.3390/ijms27052157}
}
EUVIMED